The trading price of Psyence Biomedical Ltd. (NASDAQ:PBM) closed lower on Tuesday, October 29, and closing at $0.09, -5.26% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $0.0879 and $0.095. In examining the 52-week price action we see that the stock hit a 52-week high of $14.55 and a 52-week low of $0.08. Over the past month, the stock has lost -10.00% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Psyence Biomedical Ltd., whose market valuation is $1.50 million at the time of this writing, is expected to release its quarterly earnings report in November. Investors’ optimism about the company’s current quarter earnings report is understandable.
A quick review shows that PBM’s price is currently -11.44% off the SMA20 and -52.84% off the SMA50. The RSI metric on the 14-day chart is currently showing 31.70, and weekly volatility stands at 11.30%. When measured over the past 30 days, the indicator reaches 15.14%. Psyence Biomedical Ltd. (NASDAQ:PBM)’s beta value is currently sitting at -0.48, while the Average True Range indicator is currently displaying 0.02.
To see how Psyence Biomedical Ltd. stock has been performing in comparison to its peers in the industry, here are the numbers: PBM stock’s performance was -5.26% in the latest trading, and -99.16% in the past year.
An evaluation of the daily trading volume of Psyence Biomedical Ltd. (NASDAQ:PBM) indicates that the 3-month average is 4.89 million. However, this figure has increased over the past 10 days to an average of 8.54.
Currently, records show that 13.39 million of the company’s shares remain outstanding. The insiders hold 44.17% of outstanding shares, whereas institutions hold 5.43%. The stats also highlight that short interest as of 2024-10-15, stood at 0.61 million shares, resulting in a short ratio of 0.08 at that time. From this, we can conclude that short interest is 172.00 of the company’s total outstanding shares. It is noteworthy that short shares in October were up slightly from the previous month’s figure, which was 0.38 million. However, since the stock’s price has seen -99.03% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
